You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTriazolam
Accession NumberDB00897  (APRD00313)
TypeSmall Molecule
GroupsApproved
DescriptionWithdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.
Structure
Thumb
Synonyms
Halcion
Triazolam
Triazolam
Triazolam
Triazolamum
External Identifiers
  • DEA No. 2887
  • U 33030
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-triazolam Tab 0.125mgTablet.125 mgOralAltimed Pharma Inc.1987-12-312001-09-05Canada
Alti-triazolam Tab 0.25mgTablet.25 mgOralAltimed Pharma Inc.1987-12-312001-09-05Canada
HalcionTablet0.125 mgOralPfizer Canada Inc1980-12-312006-08-02Canada
HalcionTablet.25 mg/1OralPharmacia And Upjohn Company Llc1982-11-15Not applicableUs
HalcionTablet0.25 mgOralPfizer Canada Inc1978-12-312007-05-29Canada
Mylan-triazolamTablet0.125 mgOralMylan Pharmaceuticals Ulc1992-12-312011-03-04Canada
Mylan-triazolamTablet0.25 mgOralMylan Pharmaceuticals Ulc1992-12-312011-03-04Canada
Novo-triolam Tab 0.125mgTablet.125 mgOralNovopharm Limited1990-12-312005-08-10Canada
Novo-triolam Tab 0.25mgTablet.25 mgOralNovopharm Limited1990-12-312005-08-10Canada
Penta-triazolam TabletsTablet.125 mgOralPentapharm Ltd.Not applicableNot applicableCanada
Penta-triazolam TabletsTablet.25 mgOralPentapharm Ltd.Not applicableNot applicableCanada
TriazolamTablet.25 mg/1OralGreenstone LLC1982-11-15Not applicableUs
TriazolamTablet.25 mg/1OralSTAT Rx USA LLC1982-11-15Not applicableUs
TriazolamTablet0.125 mgOralAa Pharma Inc1989-12-312014-11-07Canada
TriazolamTablet.25 mg/1OralA S Medication Solutions Llc1982-11-15Not applicableUs
TriazolamTablet.25 mg/1OralPd Rx Pharmaceuticals, Inc.1982-11-15Not applicableUs
TriazolamTablet.25 mg/1OralA S Medication Solutions Llc1982-11-15Not applicableUs
TriazolamTablet.125 mg/1OralGreenstone LLC1982-11-15Not applicableUs
TriazolamTablet0.25 mgOralAa Pharma Inc1989-12-31Not applicableCanada
Triazolam Tab 0.125mgTablet.125 mgOralPro Doc Limitee1990-12-312009-07-23Canada
Triazolam Tab 0.25mgTablet.25 mgOralPro Doc Limitee1990-12-312009-07-23Canada
Triazolam Tablets 0.125mgTablet0.125 mgOralPrempharm Inc1997-01-052005-08-05Canada
Triazolam Tablets 0.25mgTablet0.25 mgOralPrempharm Inc1997-04-302005-08-05Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TriazolamTablet.25 mg/1OralA S Medication Solutions Llc1994-06-01Not applicableUs
TriazolamTablet.125 mg/1OralRoxane Laboratories, Inc.2009-07-13Not applicableUs
TriazolamTablet.125 mg/1OralRebel Distributors Corp2009-07-13Not applicableUs
TriazolamTablet.25 mg/1Oralbryant ranch prepack1994-06-01Not applicableUs
TriazolamTablet.125 mg/1OralRoxane Laboratories, Inc.1994-06-01Not applicableUs
TriazolamTablet.25 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-06-01Not applicableUs
TriazolamTablet.25 mg/1OralAphena Pharma Solutions Tennessee, Inc.1994-06-01Not applicableUs
TriazolamTablet.25 mg/1OralRoxane Laboratories, Inc.1994-06-012016-01-30Us
TriazolamTablet.25 mg/1OralUnit Dose Services1994-06-01Not applicableUs
TriazolamTablet.25 mg/1OralPreferred Pharmaceuticals, Inc.2013-11-052016-10-13Us
TriazolamTablet.25 mg/1OralRebel Distributors Corp1994-06-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Apo-TriazoApotex
ArringYungShin
AsasionChoseido Pharmaceutical Co., Ltd
AscomarnaNisshin Seiyaku K.K
SongarValeas S.p.A.
Brand mixturesNot Available
SaltsNot Available
Categories
UNII1HM943223R
CAS number28911-01-5
WeightAverage: 343.21
Monoisotopic: 342.043901818
Chemical FormulaC17H12Cl2N4
InChI KeyJOFWLTCLBGQGBO-UHFFFAOYSA-N
InChI
InChI=1S/C17H12Cl2N4/c1-10-21-22-16-9-20-17(12-4-2-3-5-14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3
IUPAC Name
12-chloro-9-(2-chlorophenyl)-3-methyl-2,4,5,8-tetraazatricyclo[8.4.0.0²,⁶]tetradeca-1(10),3,5,8,11,13-hexaene
SMILES
CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12
Pharmacology
IndicationFor the short-term treatment of insomnia.
Structured Indications
PharmacodynamicsA short-acting benzodiazepine used as a hypnotic agent in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries. Triazolam has a shorter half-life than chlordiazepoxide, flurazepam, and prazepam and does not generate active metabolites.
Mechanism of actionBenzodiazepines bind nonspecifically to bezodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.
TargetKindPharmacological actionActionsOrganismUniProt ID
Gamma-aminobutyric acid receptor subunit alpha-1Proteinyes
potentiator
HumanP14867 details
Gamma-aminobutyric acid receptor subunit alpha-2Proteinyes
potentiator
HumanP47869 details
Gamma-aminobutyric acid receptor subunit alpha-3Proteinyes
potentiator
HumanP34903 details
Gamma-aminobutyric acid receptor subunit alpha-4Proteinyes
potentiator
HumanP48169 details
Gamma-aminobutyric acid receptor subunit alpha-5Proteinyes
potentiator
HumanP31644 details
Gamma-aminobutyric acid receptor subunit alpha-6Proteinyes
potentiator
HumanQ16445 details
Gamma-aminobutyric acid receptor subunit beta-1Proteinyes
potentiator
HumanP18505 details
Gamma-aminobutyric acid receptor subunit beta-2Proteinyes
potentiator
HumanP47870 details
Gamma-aminobutyric acid receptor subunit beta-3Proteinyes
potentiator
HumanP28472 details
Gamma-aminobutyric acid receptor subunit gamma-1Proteinyes
potentiator
HumanQ8N1C3 details
Gamma-aminobutyric acid receptor subunit gamma-2Proteinyes
potentiator
HumanP18507 details
Gamma-aminobutyric acid receptor subunit gamma-3Proteinyes
potentiator
HumanQ99928 details
Gamma-aminobutyric acid receptor subunit deltaProteinyes
potentiator
HumanO14764 details
Gamma-aminobutyric acid receptor subunit epsilonProteinyes
potentiator
HumanP78334 details
Gamma-aminobutyric acid receptor subunit piProteinyes
potentiator
HumanO00591 details
Gamma-aminobutyric acid receptor subunit rho-1Proteinyes
potentiator
HumanP24046 details
Gamma-aminobutyric acid receptor subunit rho-2Proteinyes
potentiator
HumanP28476 details
Gamma-aminobutyric acid receptor subunit rho-3Proteinyes
potentiator
HumanA8MPY1 details
Gamma-aminobutyric acid receptor subunit thetaProteinyes
potentiator
HumanQ9UN88 details
Translocator proteinProteinunknown
other
HumanP30536 details
GABA-A receptor (anion channel)Protein groupyes
positive allosteric modulator
Humannot applicabledetails
Related Articles
AbsorptionBioavailability is 44% (oral) and 53% (sublingual).
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic. Small amounts of unmetabolized triazolam appear in the urine.

SubstrateEnzymesProduct
Triazolam
4-hydroxytriazolamDetails
Triazolam
1'-hydroxytriazolamDetails
Route of eliminationTriazolam and its metabolites, principally as conjugated glucuronides, which are presumably inactive, are excreted primarily in the urine. Only small amounts of unmetabolized triazolam appear in the urine. The two primary metabolites accounted for 79.9% of urinary excretion.
Half life1.5-5.5 hours
ClearanceNot Available
ToxicitySymptoms of overdose include drowsiness, slurred speech, motor inco-ordination, coma, and respiratory depression.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Triazolam is combined with 1,1,1,2 Tetrafluoroethane.Investigational
1,10-PhenanthrolineThe serum concentration of Triazolam can be increased when it is combined with 1,10-Phenanthroline.Experimental
3,4-DichloroisocoumarinThe serum concentration of Triazolam can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Triazolam can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Triazolam is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Triazolam is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Triazolam is combined with Aceprometazine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Triazolam is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Triazolam is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Triazolam is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Triazolam.Approved, Illicit
AlogliptinThe serum concentration of Triazolam can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Triazolam can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Triazolam is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Triazolam.Approved, Illicit, Investigational
Ambroxol acefyllinateThe therapeutic efficacy of Triazolam can be decreased when used in combination with Ambroxol acefyllinate.Experimental
AminophyllineThe therapeutic efficacy of Triazolam can be decreased when used in combination with Aminophylline.Approved
AmiodaroneThe metabolism of Triazolam can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Triazolam is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Triazolam is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Triazolam is combined with Amobarbital.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Triazolam.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Triazolam is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Triazolam is combined with Amperozide.Experimental
AmprenavirThe serum concentration of Triazolam can be increased when it is combined with Amprenavir.Approved
Antithrombin III humanThe serum concentration of Triazolam can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Triazolam can be increased when it is combined with Apixaban.Approved
AprepitantThe serum concentration of Triazolam can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Triazolam can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArgatrobanThe serum concentration of Triazolam can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Triazolam is combined with Aripiprazole.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Triazolam is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Triazolam is combined with Asenapine.Approved
AsunaprevirThe serum concentration of Triazolam can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Triazolam can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Triazolam can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Azaperone.Vet Approved
AzelastineTriazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Triazolam is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Triazolam is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Triazolam is combined with Barbital.Illicit
BatimastatThe serum concentration of Triazolam can be increased when it is combined with Batimastat.Experimental
BenazeprilThe serum concentration of Triazolam can be increased when it is combined with Benazepril.Approved, Investigational
BenperidolThe risk or severity of adverse effects can be increased when Triazolam is combined with Benperidol.Investigational
BenzamidineThe serum concentration of Triazolam can be increased when it is combined with Benzamidine.Experimental
BenzocaineThe risk or severity of adverse effects can be increased when Triazolam is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Triazolam is combined with Benzyl alcohol.Approved
BexaroteneThe serum concentration of Triazolam can be decreased when it is combined with Bexarotene.Approved, Investigational
Bi201335The serum concentration of Triazolam can be increased when it is combined with Bi201335.Investigational
BivalirudinThe serum concentration of Triazolam can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Triazolam can be increased when it is combined with Boceprevir.Approved
BortezomibThe metabolism of Triazolam can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Triazolam can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Triazolam is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Triazolam is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Triazolam.Approved
BromazepamThe risk or severity of adverse effects can be increased when Triazolam is combined with Bromazepam.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Triazolam is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Triazolam.Approved, Investigational
BuprenorphineTriazolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Triazolam.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Triazolam.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Triazolam is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Triazolam is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Triazolam is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Triazolam is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Triazolam.Approved, Illicit, Vet Approved
CandoxatrilThe serum concentration of Triazolam can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Triazolam can be increased when it is combined with Candoxatrilat.Experimental
CaptoprilThe serum concentration of Triazolam can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Triazolam can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Triazolam is combined with Carbinoxamine.Approved
CarbomycinThe serum concentration of Triazolam can be increased when it is combined with Carbomycin.Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Triazolam is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Triazolam is combined with Carisoprodol.Approved
CeritinibThe serum concentration of Triazolam can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Triazolam is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Triazolam is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Triazolam.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Triazolam is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Triazolam is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Triazolam.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Triazolam is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Chlorzoxazone.Approved
ChymostatinThe serum concentration of Triazolam can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Triazolam can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Triazolam can be increased when it is combined with Cilazapril.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Triazolam.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Triazolam is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Triazolam can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Triazolam can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Triazolam is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Triazolam is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Triazolam is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Triazolam is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Triazolam is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Triazolam is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Triazolam.Approved, Illicit
ClotrimazoleThe metabolism of Triazolam can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Triazolam is combined with Clozapine.Approved
CobicistatThe serum concentration of Triazolam can be increased when it is combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Triazolam is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Triazolam.Approved, Illicit
ConivaptanThe serum concentration of Triazolam can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Triazolam can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Triazolam is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Triazolam is combined with Cyclobenzaprine.Approved
CyclosporineThe metabolism of Triazolam can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Triazolam is combined with Cyproheptadine.Approved
Dabigatran etexilateThe serum concentration of Triazolam can be increased when it is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Triazolam can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Triazolam is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Triazolam.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Triazolam is combined with Dapoxetine.Investigational
DarunavirThe serum concentration of Triazolam can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Triazolam can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Triazolam can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Triazolam can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Triazolam is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Triazolam is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Triazolam is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Triazolam is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Triazolam is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Triazolam is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Triazolam can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Triazolam is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Triazolam.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Triazolam is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Triazolam.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Triazolam is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Triazolam.Approved, Illicit, Vet Approved
DifenoxinThe risk or severity of adverse effects can be increased when Triazolam is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Triazolam is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Triazolam can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Triazolam is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Triazolam is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Triazolam can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Triazolam is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Triazolam is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Triazolam is combined with Diphenoxylate.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Triazolam is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Triazolam is combined with Doxepin.Approved
DoxycyclineThe metabolism of Triazolam can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Triazolam.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Triazolam is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Triazolam.Approved, Illicit
DronedaroneThe metabolism of Triazolam can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Triazolam.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Triazolam is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Triazolam is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Triazolam.Approved
DyphyllineThe therapeutic efficacy of Triazolam can be decreased when used in combination with Dyphylline.Approved
EcabetThe serum concentration of Triazolam can be increased when it is combined with Ecabet.Approved, Investigational
EcgonineThe risk or severity of adverse effects can be increased when Triazolam is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Triazolam is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Triazolam can be increased when it is combined with Edoxaban.Approved
EfavirenzThe serum concentration of Triazolam can be decreased when it is combined with Efavirenz.Approved, Investigational
ElafinThe serum concentration of Triazolam can be increased when it is combined with Elafin.Investigational
EnalaprilThe serum concentration of Triazolam can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Triazolam can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Triazolam can be increased when it is combined with Enalkiren.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Triazolam.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Triazolam is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Triazolam can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe serum concentration of Triazolam can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Triazolam is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Triazolam can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Triazolam.Approved
EthanolTriazolam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Triazolam.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Triazolam is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Triazolam is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Triazolam is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Triazolam is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Triazolam is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Triazolam is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Triazolam is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Triazolam.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Triazolam is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Triazolam can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Triazolam is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Triazolam is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Triazolam is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Triazolam.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Triazolam is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Triazolam is combined with Flibanserin.Approved
FluconazoleThe metabolism of Triazolam can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Triazolam is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Triazolam is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Triazolam is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Triazolam is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Triazolam.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Triazolam.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Triazolam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Triazolam is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Triazolam is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Triazolam can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Triazolam can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Triazolam can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Triazolam can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Triazolam.Approved
FospropofolThe risk or severity of adverse effects can be increased when Triazolam is combined with Fospropofol.Approved, Illicit
Fusidic AcidThe serum concentration of Triazolam can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Triazolam is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Triazolam is combined with gabapentin enacarbil.Approved
GabexateThe serum concentration of Triazolam can be increased when it is combined with Gabexate.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Triazolam is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GeldanamycinThe serum concentration of Triazolam can be increased when it is combined with Geldanamycin.Experimental
GepironeThe risk or severity of adverse effects can be increased when Triazolam is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Triazolam is combined with Glutethimide.Approved, Illicit
GM6001The serum concentration of Triazolam can be increased when it is combined with GM6001.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Triazolam is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Triazolam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Triazolam.Approved
HalothaneThe risk or severity of adverse effects can be increased when Triazolam is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Triazolam is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Triazolam is combined with Hexobarbital.Approved
HirulogThe serum concentration of Triazolam can be increased when it is combined with Hirulog.Experimental
HyaluronidaseThe therapeutic efficacy of Triazolam can be decreased when used in combination with Hyaluronidase.Approved, Investigational
HydrocodoneTriazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Triazolam.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Triazolam.Approved
IdelalisibThe serum concentration of Triazolam can be increased when it is combined with Idelalisib.Approved
idraparinuxThe serum concentration of Triazolam can be increased when it is combined with idraparinux.Investigational
IloperidoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Iloperidone.Approved
ImatinibThe metabolism of Triazolam can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Triazolam can be increased when it is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Triazolam is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Triazolam is combined with Indalpine.Investigational, Withdrawn
IndinavirThe serum concentration of Triazolam can be increased when it is combined with Indinavir.Approved
IsavuconazoniumThe metabolism of Triazolam can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Triazolam.Approved, Vet Approved
IsoflurophateThe serum concentration of Triazolam can be increased when it is combined with Isoflurophate.Approved, Withdrawn
IsradipineThe metabolism of Triazolam can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Triazolam can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Triazolam can be increased when it is combined with Ivacaftor.Approved
IxazomibThe serum concentration of Triazolam can be increased when it is combined with Ixazomib.Approved
JosamycinThe serum concentration of Triazolam can be increased when it is combined with Josamycin.Approved
KetamineThe risk or severity of adverse effects can be increased when Triazolam is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Ketobemidone.Approved
KetoconazoleThe serum concentration of Triazolam can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoconazoleThe metabolism of Triazolam can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe serum concentration of Triazolam can be increased when it is combined with Kitasamycin.Experimental
LamotrigineThe risk or severity of adverse effects can be increased when Triazolam is combined with Lamotrigine.Approved, Investigational
LepirudinThe serum concentration of Triazolam can be increased when it is combined with Lepirudin.Approved
LevetiracetamThe risk or severity of adverse effects can be increased when Triazolam is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Triazolam is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Triazolam is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Triazolam is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Triazolam is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Triazolam is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Triazolam is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Triazolam.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Triazolam.Approved, Vet Approved
LinagliptinThe serum concentration of Triazolam can be increased when it is combined with Linagliptin.Approved
LisinoprilThe serum concentration of Triazolam can be increased when it is combined with Lisinopril.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Triazolam is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Triazolam is combined with Lofentanil.Illicit
LopinavirThe serum concentration of Triazolam can be increased when it is combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Triazolam is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Triazolam.Approved
LovastatinThe metabolism of Triazolam can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Triazolam.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Triazolam is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Triazolam can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Triazolam can be increased when combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Triazolam.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Triazolam is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Triazolam is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Triazolam is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Triazolam is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Triazolam is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Triazolam.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Triazolam is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Triazolam is combined with Metaxalone.Approved
MethadoneTriazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Triazolam is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Triazolam is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Triazolam is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Triazolam.Approved
MethotrimeprazineTriazolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Triazolam is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Triazolam is combined with Methsuximide.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Triazolam.Approved
MetyrosineTriazolam may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Triazolam.Approved, Illicit
MifepristoneThe serum concentration of Triazolam can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Triazolam is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Triazolam.Approved, Investigational
MirtazapineTriazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Triazolam can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Triazolam can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Triazolam can be increased when it is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Triazolam.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Triazolam can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Triazolam.Approved, Investigational
NafamostatThe serum concentration of Triazolam can be increased when it is combined with Nafamostat.Investigational
NafcillinThe serum concentration of Triazolam can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Triazolam.Approved
NCX 4016The serum concentration of Triazolam can be increased when it is combined with NCX 4016.Investigational
NefazodoneThe metabolism of Triazolam can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Triazolam can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Triazolam can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Triazolam can be increased when combined with Nevirapine.Approved
NilotinibThe metabolism of Triazolam can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Triazolam is combined with Nitrazepam.Approved
NitroaspirinThe serum concentration of Triazolam can be increased when it is combined with Nitroaspirin.Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Triazolam is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Triazolam is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Triazolam.Approved, Investigational
OlaparibThe metabolism of Triazolam can be decreased when combined with Olaparib.Approved
OleandomycinThe serum concentration of Triazolam can be increased when it is combined with Oleandomycin.Vet Approved
OlopatadineThe risk or severity of adverse effects can be increased when Triazolam is combined with Olopatadine.Approved
OmapatrilatThe serum concentration of Triazolam can be increased when it is combined with Omapatrilat.Investigational
OndansetronThe risk or severity of adverse effects can be increased when Triazolam is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Triazolam is combined with Opium.Approved, Illicit
OrphenadrineTriazolam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Triazolam is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Triazolam can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Triazolam can be increased when it is combined with Otamixaban.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Triazolam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Triazolam is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Triazolam is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Triazolam.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Triazolam.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Oxymorphone.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Triazolam can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Paliperidone.Approved
ParaldehydeTriazolam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Triazolam is combined with Paroxetine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Triazolam.Approved, Vet Approved
PentobarbitalThe metabolism of Triazolam can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Triazolam.Approved
PerazineThe risk or severity of adverse effects can be increased when Triazolam is combined with Perazine.Investigational
PerindoprilThe serum concentration of Triazolam can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Triazolam is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Triazolam.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Triazolam.Approved
PhenobarbitalThe metabolism of Triazolam can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Triazolam is combined with Phenoxyethanol.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Triazolam.Approved, Vet Approved
PhosphoramidonThe serum concentration of Triazolam can be increased when it is combined with Phosphoramidon.Experimental
PimozideThe risk or severity of adverse effects can be increased when Triazolam is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Triazolam is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Triazolam is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Triazolam is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Triazolam is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Triazolam is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Triazolam can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleTriazolam may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Triazolam is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Triazolam is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Triazolam.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Triazolam is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Triazolam.Approved
PrimidoneThe metabolism of Triazolam can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Triazolam can be increased when it is combined with Prinomastat.Investigational
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Triazolam.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Triazolam.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Triazolam.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Triazolam is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Triazolam.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Triazolam.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Triazolam is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Triazolam is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Triazolam is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Triazolam is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Triazolam is combined with Quetiapine.Approved
QuinaprilThe serum concentration of Triazolam can be increased when it is combined with Quinapril.Approved, Investigational
RacecadotrilThe serum concentration of Triazolam can be increased when it is combined with Racecadotril.Investigational
RacloprideThe risk or severity of adverse effects can be increased when Triazolam is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Triazolam is combined with Ramelteon.Approved, Investigational
RamiprilThe serum concentration of Triazolam can be increased when it is combined with Ramipril.Approved
RanolazineThe metabolism of Triazolam can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Triazolam is combined with Remifentanil.Approved
RemikirenThe serum concentration of Triazolam can be increased when it is combined with Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Triazolam.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Triazolam.Approved
RifabutinThe metabolism of Triazolam can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Triazolam can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Triazolam can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Triazolam.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Triazolam is combined with Ritanserin.Investigational
RitonavirThe serum concentration of Triazolam can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Triazolam can be increased when it is combined with Rivaroxaban.Approved
RomifidineThe risk or severity of adverse effects can be increased when Triazolam is combined with Romifidine.Vet Approved
RopiniroleTriazolam may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Triazolam.Approved
RotigotineTriazolam may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Triazolam.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Triazolam is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Triazolam is combined with Sage 547.Investigational
SaquinavirThe serum concentration of Triazolam can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Triazolam can be increased when it is combined with Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Triazolam is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Triazolam.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Triazolam is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Triazolam is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Triazolam is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Triazolam can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Triazolam can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Triazolam can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Triazolam can be increased when it is combined with Sitagliptin.Approved, Investigational
Sodium oxybateTriazolam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.Approved
SolithromycinThe serum concentration of Triazolam can be increased when it is combined with Solithromycin.Investigational
SpiraprilThe serum concentration of Triazolam can be increased when it is combined with Spirapril.Approved
St. John's WortThe serum concentration of Triazolam can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Triazolam can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Triazolam.Approved, Investigational
SulfisoxazoleThe metabolism of Triazolam can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Triazolam.Approved
SuvorexantTriazolam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Triazolam is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Triazolam.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Triazolam is combined with Tasimelteon.Approved
TeduglutideThe serum concentration of Triazolam can be increased when it is combined with Teduglutide.Approved
TelaprevirThe serum concentration of Triazolam can be increased when it is combined with Telaprevir.Approved
TelithromycinThe serum concentration of Triazolam can be increased when it is combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Triazolam.Approved
TemocaprilThe serum concentration of Triazolam can be increased when it is combined with Temocapril.Experimental, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Triazolam is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Triazolam is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Triazolam is combined with Tetrodotoxin.Investigational
ThalidomideTriazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe therapeutic efficacy of Triazolam can be decreased when used in combination with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Triazolam is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Triazolam.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Triazolam.Approved
ThiorphanThe serum concentration of Triazolam can be increased when it is combined with Thiorphan.Experimental
ThiothixeneThe risk or severity of adverse effects can be increased when Triazolam is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Triazolam is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Triazolam is combined with Tiapride.Investigational
TiclopidineThe metabolism of Triazolam can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Triazolam is combined with Tiletamine.Vet Approved
TipranavirThe serum concentration of Triazolam can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Triazolam is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Triazolam can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Triazolam is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Triazolam is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Triazolam.Approved, Investigational
TrandolaprilThe serum concentration of Triazolam can be increased when it is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Triazolam is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Triazolam.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Triazolam.Approved, Investigational
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Triazolam.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Triazolam.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Triazolam is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triazolam is combined with Triprolidine.Approved
TroleandomycinThe serum concentration of Triazolam can be increased when it is combined with Troleandomycin.Approved
TylosinThe serum concentration of Triazolam can be increased when it is combined with Tylosin.Vet Approved
UbenimexThe serum concentration of Triazolam can be increased when it is combined with Ubenimex.Experimental
Uc1010The risk or severity of adverse effects can be increased when Triazolam is combined with Uc1010.Investigational
UlinastatinThe serum concentration of Triazolam can be increased when it is combined with Ulinastatin.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Triazolam.Approved, Investigational
VenlafaxineThe metabolism of Triazolam can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Triazolam can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Triazolam is combined with Vigabatrin.Approved
VildagliptinThe serum concentration of Triazolam can be increased when it is combined with Vildagliptin.Approved, Investigational
VoriconazoleThe metabolism of Triazolam can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Triazolam is combined with Vortioxetine.Approved
XimelagatranThe serum concentration of Triazolam can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineThe risk or severity of adverse effects can be increased when Triazolam is combined with Xylazine.Vet Approved
Ym150The serum concentration of Triazolam can be increased when it is combined with Ym150.Investigational
YohimbineThe therapeutic efficacy of Triazolam can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Triazolam is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Triazolam is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Triazolam is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Triazolam can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Triazolam is combined with Zolazepam.Vet Approved
ZolpidemTriazolam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Triazolam is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Triazolam is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Triazolam is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Triazolam is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Rickels K: The clinical use of hypnotics: indications for use and the need for a variety of hypnotics. Acta Psychiatr Scand Suppl. 1986;332:132-41. [PubMed:2883820 ]
  2. Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines]. Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [PubMed:2570451 ]
  3. Noguchi H, Kitazumi K, Mori M, Shiba T: Electroencephalographic properties of zaleplon, a non-benzodiazepine sedative/hypnotic, in rats. J Pharmacol Sci. 2004 Mar;94(3):246-51. [PubMed:15037809 ]
  4. Tokunaga S, Takeda Y, Shinomiya K, Hirase M, Kamei C: Effects of some H1-antagonists on the sleep-wake cycle in sleep-disturbed rats. J Pharmacol Sci. 2007 Feb;103(2):201-6. Epub 2007 Feb 8. [PubMed:17287588 ]
  5. Veje JO, Andersen K, Gjesing S, Kielgast H: [Prescription of tranquilizers and hypnotics in the municipality of Holbaek]. Ugeskr Laeger. 1989 Aug 21;151(34):2134-6. [PubMed:2773144 ]
External Links
ATC CodesN05CD05
AHFS Codes
  • 28:24.08
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (5.44 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9719
Caco-2 permeable+0.886
P-glycoprotein substrateNon-substrate0.5252
P-glycoprotein inhibitor INon-inhibitor0.6788
P-glycoprotein inhibitor IIInhibitor0.8331
Renal organic cation transporterInhibitor0.7628
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9208
CYP450 3A4 substrateSubstrate0.751
CYP450 1A2 substrateInhibitor0.8598
CYP450 2C9 inhibitorInhibitor0.815
CYP450 2D6 inhibitorNon-inhibitor0.8226
CYP450 2C19 inhibitorInhibitor0.7117
CYP450 3A4 inhibitorNon-inhibitor0.5596
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9088
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.6714
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.9971 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9638
hERG inhibition (predictor II)Non-inhibitor0.8806
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Pharmacia and upjohn co
  • Alphapharm party ltd
  • Roxane laboratories inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
TabletOral0.125 mg
TabletOral.125 mg
TabletOral.25 mg
TabletOral.125 mg/1
TabletOral.25 mg/1
TabletOral0.25 mg
Prices
Unit descriptionCostUnit
Halcion 10 0.25 mg tablet Bottle21.0USD bottle
Triazolam 10 0.125 mg tablet Bottle6.33USD bottle
Triazolam 10 0.25 mg tablet Bottle6.0USD bottle
Halcion 0.25 mg tablet1.99USD tablet
Halcion 0.125 mg tablet1.37USD tablet
Triazolam 0.25 mg tablet0.67USD tablet
Triazolam 0.125 mg tablet0.65USD tablet
Apo-Triazo 0.25 mg Tablet0.22USD tablet
Mylan-Triazolam 0.25 mg Tablet0.22USD tablet
Apo-Triazo 0.125 mg Tablet0.12USD tablet
Mylan-Triazolam 0.125 mg Tablet0.12USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point233-235 °CNot Available
water solubility4.53 mg/LNot Available
logP2.42BIOBYTE (1995)
logS-4.08ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0183 mg/mLALOGPS
logP2.94ALOGPS
logP2.89ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)18.08ChemAxon
pKa (Strongest Basic)4.32ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area43.07 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity103.68 m3·mol-1ChemAxon
Polarizability34.19 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0imr-4954000000-75bcea16a1182103168fView in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub Class1,4-benzodiazepines
Direct Parent1,4-benzodiazepines
Alternative Parents
Substituents
  • 1,4-benzodiazepine
  • Phenyl-1,3,4-triazole
  • Phenyl-1,2,4-triazole
  • Phenyltriazole
  • Halobenzene
  • Chlorobenzene
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • 1,2,4-triazole
  • Triazole
  • Azole
  • Ketimine
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Imine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA4
Uniprot ID:
P48169
Molecular Weight:
61622.645 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA6
Uniprot ID:
Q16445
Molecular Weight:
51023.69 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRB1
Uniprot ID:
P18505
Molecular Weight:
54234.085 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB2
Uniprot ID:
P47870
Molecular Weight:
59149.895 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-gated chloride ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB3
Uniprot ID:
P28472
Molecular Weight:
54115.04 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG1
Uniprot ID:
Q8N1C3
Molecular Weight:
53594.49 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRG2
Uniprot ID:
P18507
Molecular Weight:
54161.78 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG3
Uniprot ID:
Q99928
Molecular Weight:
54288.16 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRD
Uniprot ID:
O14764
Molecular Weight:
50707.835 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRE
Uniprot ID:
P78334
Molecular Weight:
57971.175 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the uterus, the function of the receptor appears to be related to tissue contractility. The binding of this pI subunit with other GABA(A) receptor subunits alters the sensitivity of recombinant receptors to ...
Gene Name:
GABRP
Uniprot ID:
O00591
Molecular Weight:
50639.735 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR1
Uniprot ID:
P24046
Molecular Weight:
55882.91 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR2
Uniprot ID:
P28476
Molecular Weight:
54150.41 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRR3
Uniprot ID:
A8MPY1
Molecular Weight:
54271.1 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transmembrane signaling receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRQ
Uniprot ID:
Q9UN88
Molecular Weight:
72020.875 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other
General Function:
Cholesterol binding
Specific Function:
Can bind protoporphyrin IX and may play a role in the transport of porphyrins and heme (By similarity). Promotes the transport of cholesterol across mitochondrial membranes and may play a role in lipid metabolism (PubMed:24814875), but its precise physiological role is controversial. It is apparently not required for steroid hormone biosynthesis. Was initially identified as peripheral-type benz...
Gene Name:
TSPO
Uniprot ID:
P30536
Molecular Weight:
18827.81 Da
References
  1. Park CH, Carboni E, Wood PL, Gee KW: Characterization of peripheral benzodiazepine type sites in a cultured murine BV-2 microglial cell line. Glia. 1996 Jan;16(1):65-70. [PubMed:8787774 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. ChEMBL Compound Report Card [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA: Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos. 2002 Aug;30(8):883-91. [PubMed:12124305 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23